GH Secretagogue Stacks

What Is GH Secretagogue Stacks?

Growth hormone secretagogue stacks combine two classes of peptides — GHRH analogs (which amplify GH production) and GHRPs (which trigger GH release) — for synergistic growth hormone optimization. The most common stacks pair a GHRH analog with a GHRP, producing GH pulses that are 3-5x greater than either class alone.

The rationale is mechanistic: GHRH analogs (sermorelin, MOD-GRF 1-29, CJC-1295) act on GHRH receptors to increase the amount of GH available for release. GHRPs (ipamorelin, GHRP-2, GHRP-6, hexarelin) act on ghrelin receptors to trigger the release pulse. Together, they provide both the 'fuel' and the 'spark' for robust, physiological GH secretion.

Common stacks include: MOD-GRF 1-29 + Ipamorelin (most popular, cleanest profile), CJC-1295 with DAC + Ipamorelin (less frequent dosing), Sermorelin + Ipamorelin (well-established), and Tesamorelin + Ipamorelin (when FDA-approved GHRH is preferred).

What The Research Says

Research consistently shows that GHRH + GHRP combinations produce synergistic GH release. In clinical studies, the combination of GHRH analogs with GHRPs produces GH peaks 5-10x above baseline — significantly more than either agent alone. The synergy is due to complementary receptor systems.

IGF-1 normalization is the primary measurable endpoint used to guide dosing. Clinical outcomes include improved body composition, better sleep architecture, enhanced recovery from injury, and improved energy levels. The combination approach allows lower doses of each component, potentially reducing side effects.

📚 Key Reference: PMID: 16882916 (GHRH/GHRP synergy)

Common Uses

• Growth hormone deficiency (adult)
• Body composition optimization
• Sleep quality enhancement
• Recovery from injury/surgery
• Anti-aging protocols
• Athletic recovery (note: WADA banned)

Important Safety Information

Side effects relate to GH elevation: water retention, joint pain, carpal tunnel, glucose intolerance. These are dose-dependent and usually resolve with dose adjustment. Regular IGF-1 monitoring prevents over-treatment. Contraindicated in active malignancy. Consult your provider for appropriate combination and dosing.

Questions To Ask Your Provider

1. Which GHRH + GHRP combination is recommended for my goals?
2. What are my baseline and target IGF-1 levels?
3. What is the timing protocol (before bed, morning, etc.)?
4. How often will labs be monitored?
5. What compounding pharmacy provides the peptides?

Regulatory Status

Individual components vary in regulatory status. None are FDA-approved as combination stacks. Compounding is under 503A/503B regulations. WADA prohibited for competitive athletes.